| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Armillarisin A does not have a well-defined pharmacological target. Its biological effects are related to its immunomodulatory activity. It upregulates IL-4 and downregulates IL-1β. By modulating these cytokines, armillarisin A may exert anti-inflammatory effects. It may also modulate specific signaling pathways involved in cell proliferation, apoptosis, and immune response.
|
|---|---|
| ln Vitro |
In vitro, armillarisin A upregulates IL-4 and downregulates IL-1β. These immunomodulatory effects have been demonstrated in cell-based assays. The compound's ability to modulate cytokine production suggests potential anti-inflammatory activity. However, specific details of in vitro studies are not extensively detailed in the available literature.
|
| ln Vivo |
In vivo, armillarisin A has potential usefulness in ulcerative colitis (UC) research. It may exert anti-inflammatory effects by modulating cytokine production. However, specific details of in vivo efficacy studies, such as the animal models used and the dosing regimens, are not extensively detailed in the available literature. The compound is a natural product with potential for further research.
|
| Enzyme Assay |
Armillarisin A does not have a classical enzyme/receptor binding assay, as its mechanism of action is not well-defined. Its immunomodulatory effects are typically studied in cellular systems. Its effects on cytokine production can be assessed in immune cells using ELISA or other immunoassays. These assays provide a measure of the compound's functional activity.
|
| Cell Assay |
In vitro cellular assays for armillarisin A assess its effects on cytokine production in immune cells. Cells such as macrophages or lymphocytes are treated with armillarisin A, and the production of IL-4 and IL-1β is measured. These assays demonstrate the compound's immunomodulatory effects in a relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for armillarisin A have been conducted in models of ulcerative colitis to assess its efficacy. However, specific details of these studies are not extensively detailed in the available literature. The compound is a natural product with potential for further research in inflammatory bowel disease.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for armillarisin A are not extensively detailed in the available literature. As a natural product, its oral bioavailability may be limited. However, its in vivo efficacy suggests that it reaches sufficient systemic concentrations to exert its effects. The compound's pharmacokinetic properties would be important for its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for armillarisin A are not extensively detailed in the available literature. As a natural product, it is generally considered to have low toxicity. However, comprehensive toxicological studies would be required to establish its safety profile for therapeutic use. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Armillarisin A is a bioactive compound extracted from Armillaria mushrooms with potential usefulness in ulcerative colitis research. It upregulates IL-4 and downregulates IL-1β. It works by modulating specific signaling pathways involved in cell proliferation, apoptosis, and immune response. It is a research compound and is not approved for clinical use.
|
| Molecular Formula |
C12H10O5
|
|---|---|
| Molecular Weight |
234.2048
|
| Exact Mass |
234.052
|
| CAS # |
53696-74-5
|
| PubChem CID |
5320192
|
| Appearance |
Light yellow to green yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
565.0±50.0 °C at 760 mmHg
|
| Melting Point |
250-255ºC
|
| Flash Point |
227.2±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
0.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
373
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XVZWWNMZVZWQKU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10O5/c1-6(14)9-4-10-7(5-13)2-8(15)3-11(10)17-12(9)16/h2-4,13,15H,5H2,1H3
|
| Chemical Name |
3-acetyl-7-hydroxy-5-(hydroxymethyl)chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~426.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (10.67 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (10.67 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2699 mL | 21.3493 mL | 42.6985 mL | |
| 5 mM | 0.8540 mL | 4.2699 mL | 8.5397 mL | |
| 10 mM | 0.4270 mL | 2.1349 mL | 4.2699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
